Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Engineered Virus Designed to Fight Triple-Negative Breast Cancer

By BiotechDaily International staff writers
Posted on 11 Feb 2014
Image: Breast cancer cell. Triple-negative breast cancer is an aggressive disease with few therapeutic options. Patients with such tumors can be treated only with chemotherapy (Photo courtesy of the National Cancer Institute).
Image: Breast cancer cell. Triple-negative breast cancer is an aggressive disease with few therapeutic options. Patients with such tumors can be treated only with chemotherapy (Photo courtesy of the National Cancer Institute).
ADVERTISEMENT
SARTORIUS AG
Scientists have found a possible cure for one of the most deadly, aggressive, and least treatable forms of breast cancer called triple-negative breast cancer (TNBC). In laboratory research involving human cancer cells, scientists exploited a virus comparable to the one that helped eradicate smallpox to persuade cancer cells to generate a protein that makes them disposed to radioactive iodine.

The new findings were published in the February 2014 issue of Federation of American Societies for Experimental Biology’s the FASEB Journal. “We hope that the recent developments in genetic engineering, virology, and targeted radiotherapy will soon translate into an entire class of innovative oncolytic virotherapies for the treatment of deadly cancers,” said Yuman Fong, MD, a researcher involved in the work from the department of surgery at Memorial Sloan-Kettering Cancer Center (New York, NY, USA).

In the study, Dr. Fong and colleagues effectively infected and destroyed TNBC cells using a Vaccinia virus. Furthermore, the researchers were also able to utilize the virus to cause infected cancer cells produce a cell surface protein called hNIS (human Na+/I- symporter) that typically is used to concentrate iodine in thyroid cells. Expressed in thyroid cancer, the hNIS protein is why most thyroid cancers can be cured or successfully treated with a small dose of radioactive iodine, killing thyroid cancer cells expressing hNIS in the process. Equipped with the ability to compel TNBC cells to produce this protein, researchers now have a way to deliver anticancer treatments to this lethal and resistant form of cancer.

“This is an important and significant discovery that basically combines proven cures for two other diseases,” said Gerald Weissmann, MD, editor-in-chief of the FASEB Journal. “Even more exciting is that the effects of this virus and radioactive iodine are well known in people, hopefully reducing the amount of time it will take for it to reach the clinic.”

Related Links:

Memorial Sloan-Kettering Cancer Center



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.